Cefminox sodium
Based on 1 publication(s) in Google Scholar
Cefminox sodium (MT-141) is a semisynthetic cephamycin, which exhibits antibacterial activity. Cefminox sodium is a broad-spectrum, bactericidal cephalosporin antibiotic. Cefminox sodium also acts as a dual agonist of prostacyclin receptor (IP) and PPARγ. Cefminox sodium upregulates cAMP production and PTEN expression and inhibits Akt/mTOR signaling. Cefminox sodium also prevents pulmonary arterial hypertension in rat model.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.83%
- No. CAS: 75498-96-3
- Fòrmula: C16H20N7NaO7S3
- Peso molecular:541.56
-
Almacenamiento:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Lactylation Compound Library
HY-L249
-
Anti-Infection Compound Library
HY-L002
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
PI3K/Akt/mTOR Compound Library
HY-L015
-
Stem Cell Signaling Compound Library
HY-L017
-
FDA-Approved Drug Library
HY-L022
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Antioxidant Compound Library
HY-L037
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Endocrinology Compound Library
HY-L047
-
Antibacterial Compound Library
HY-L049
-
NMPA-Approved Drug Library
HY-L053
-
Glycolysis Compound Library
HY-L058
-
Cytoskeleton Compound Library
HY-L060
-
Glutamine Metabolism Compound Library
HY-L064
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Obesity Compound Library
HY-L087
-
Angiogenesis-Related Compound Library
HY-L088
-
Transcription Factor-Targeted Library
HY-L090
-
Lipid Metabolism Compound Library
HY-L091
-
Glucose Metabolism Compound Library
HY-L092
-
Antidepressant Compound Library
HY-L108
-
Nuclear Receptor Compound Library
HY-L126
-
Osteogenesis Compound Library
HY-L131
-
Cancer Stem Cells Compound Library
HY-L135
-
Coagulation and Anti-coagulation Compound Library
HY-L136
-
Pain-Related Compound Library
HY-L139
-
Off-patent Drug Library
HY-L141
-
Mitochondrial Protection Compound Library
HY-L144
-
Metabolic Enzyme Compound Library
HY-L146
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Cefminox sodium
MoreVer todos los productos específicos de isoformas Antibiotic
More
Actividad biológica
|
PPARγ |
IP Receptor |
Bacterial |
Cefminox sodium (Compound MT-141) (0.1-800 μg/mL) is more active against gram-negative and anaerobic bacteria than against gram-positive bacteria[1].
Cefminox sodium (10-50 μM, 48 h) significantly inhibits the hypoxia-induced cell proliferation dose-dependently in primary pulmonary artery smooth muscle cells (PASMCs) through the enhancement of both IP and PPARγ activities[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Primary pulmonary artery smooth muscle cells (PASMCs)
-
Concentration:10 and 50 μM
-
Incubation Time:48 h
-
Result:Increased PTEN mRNA levels.
Increased PTEN protein levels in both normoxic and hypoxic conditions.
Inhibited the Akt/mTOR signaling pathway through elevation of PTEN protein levels.
Inhibited cell growth by up-regulation PTEN expression and inhibiting Akt/mTOR signaling in PASMCs under hypoxic conditions.
Cefminox sodium (1-1000 mg/kg, s.c., single dose) gives dose-related serum levels in male Slc:ddY mice[1].
Cefminox sodium (160-320 mg/kg/day, i.v., single dose) significantly decreases mean pulmonary artery pressure (mPAP) in male SD rats with hypoxia-induced pulmonary hypertension (HPH)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Adult male Sprague Dawley (SD) rats (150-200 g) with hypoxia-induced pulmonary hypertension (HPH)[2]
-
Dosage:160 and 320 mg/kg/day
-
Administration:Intravenous injection (i.v.) in tail, single dose
-
Result:Significantly decreased mean pulmonary artery pressure (mPAP) dose-dependently.
Significantly reversed hypoxia-induced pulmonary artery remodeling by decreasing the number of smooth muscle cells.
Increased the expression of PTEN compared with that in the normoxia or hypoxia (no treatment) groups.
Chemical Information
-
No. CAS 75498-96-3
-
Appearance Solid
-
Peso molecular 541.56
-
Fòrmula C16H20N7NaO7S3
-
Color White to off-white
-
SMILES
O=C(C(N12)=C(CSC3=NN=NN3C)CS[C@]2([H])[C@](OC)(NC(CSC[C@@H](N)C(O)=O)=O)C1=O)O[Na]
-
Synonyms
MT-141
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Heliyon
Cefminox sodium alleviates the high-fat high-sugar-fed mice's hepatic fatty accumulation via multiple pathways. [Abstract]2023 Nov 7;9(11):e21973. PMID: 38027801
Solvente y solubilidad
H2O : 83.33 mg/mL (153.87 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 50 mg/mL (92.33 mM); Clear solution; Need ultrasonic
Pureza y Documentación
-
Ficha de datos (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Inouye S, et al. In vitro and in vivo antibacterial activities of MT-141, a new semisynthetic cephamycin, compared with those of five cephalosporins. Antimicrob Agents Chemother. 1984 Nov;26(5):722-9. [Content Brief]
[2]. Xia J, et al. Cefminox, a Dual Agonist of Prostacyclin Receptor and Peroxisome Proliferator-Activated Receptor-Gamma Identified by Virtual Screening, Has Therapeutic Efficacy against Hypoxia-Induced Pulmonary Hypertension in Rats. Front Pharmacol. 2018 Feb 23;9:134. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 1.8465 mL | 9.2326 mL | 18.4652 mL | 46.1629 mL |
| 5 mM | 0.3693 mL | 1.8465 mL | 3.6930 mL | 9.2326 mL | |
| 10 mM | 0.1847 mL | 0.9233 mL | 1.8465 mL | 4.6163 mL | |
| 15 mM | 0.1231 mL | 0.6155 mL | 1.2310 mL | 3.0775 mL | |
| 20 mM | 0.0923 mL | 0.4616 mL | 0.9233 mL | 2.3081 mL | |
| 25 mM | 0.0739 mL | 0.3693 mL | 0.7386 mL | 1.8465 mL | |
| 30 mM | 0.0616 mL | 0.3078 mL | 0.6155 mL | 1.5388 mL | |
| 40 mM | 0.0462 mL | 0.2308 mL | 0.4616 mL | 1.1541 mL | |
| 50 mM | 0.0369 mL | 0.1847 mL | 0.3693 mL | 0.9233 mL | |
| 60 mM | 0.0308 mL | 0.1539 mL | 0.3078 mL | 0.7694 mL | |
| 80 mM | 0.0231 mL | 0.1154 mL | 0.2308 mL | 0.5770 mL | |
| 100 mM | 0.0185 mL | 0.0923 mL | 0.1847 mL | 0.4616 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Cefminox sodium Related Classifications
HY-128932 Related Classifications
Powered by Bioz